Lir Lir Life Science聘请了一家公司来推动投资者的拓展,在数字运动上花费75万加拿大第纳尔,以推广其非注射性肥胖药物。 Lir Life Sciences hired a firm to boost investor outreach, spending CAD 750,000 on digital campaigns to advance its non-injectable obesity drug.

Lir生命科学公司雇用了MCS市场通信服务公司提供数字投资者关系服务,包括运动发展和在线广告,直到2026年5月17日或直至资金用完为止。 Lir Life Sciences Corp. has hired MCS Market Communication Service GmbH to provide digital investor relations services, including campaign development and online advertising, through May 17, 2026 or until funds are exhausted. 该公司为服务支付了750 000加拿大第纳尔,理由是全球需求不断上升,以及作为成本驱动因素的加拿大元疲软。 The company paid CAD 750,000 for the services, citing rising global demand and a weaker Canadian dollar as cost drivers. 支出符合CSE政策7.2,目的是提高品牌知名度和吸引投资者。 The expenditure, which complies with CSE Policy 7.2, is intended to boost brand visibility and attract investors. Lir预计保持足够的现金,以便通过临床前的重要里程碑,包括小型猪研究、配方开发和保障成分,推进其GLP-1转基因补丁方案,同时扩大其知识产权范围。 Lir expects to maintain sufficient cash to advance its GLP-1 transdermal patch program through key pre-clinical milestones, including Mini Pig studies, formulation development, and securing ingredients, while also expanding its intellectual property. 该公司注重发展负担得起的、非注射性肥胖症治疗。 The company focuses on developing affordable, non-injectable obesity treatments.